Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

Rhea-AI Summary

Shuttle Pharmaceuticals Holdings (NASDAQ: SHPH) has appointed George Scorsis as Chairman of the Board of Directors, effective June 4, 2025. Scorsis, who has served as a director since February 2025, brings over 25 years of experience leading companies in regulated industries. His extensive leadership background includes roles as President at Mettrum Health Corp, CEO of Liberty Health Sciences, and Chairman positions at SOL Global Investments, Entourage Health Corp, and AWAKN Life Sciences. Shuttle Pharma is focused on developing radiation sensitizers to enhance cancer treatment outcomes, specifically targeting improved cure rates, patient survival, and quality of life for patients undergoing radiation therapy.

Positive

• Appointment of experienced chairman with 25+ years of leadership in regulated industries
• New chairman has proven track record of leading companies to rapid growth
• Multiple board leadership experiences in publicly traded companies

Negative

• New chairman's primary experience is in cannabis and biotech, not specifically in radiation therapy or cancer treatment
• Relatively short tenure with company as director (since February 2025) before becoming chairman

GAITHERSBURG, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of George Scorsis as the Chairman of the Board of Directors. Mr. Scorsis has served as director of the Company since February 2025.

Mr. Scorsis has over 25 years of experience leading companies in highly regulated industries to rapid growth, including alcohol, energy drinks, and Biotech. From October 2015 to July 2017, Mr. Scorsis worked as President at Mettrum Health Corp., a leading Canadian cannabis distributor. From July 2017 to February 2019, Mr. Scorsis served as the Chief Executive Officer and Director of Liberty Health Sciences. From January 2015 to April 2018, Mr. Scorsis has served as Chairman of the Board of Directors of SOL Global Investments Corp. (formerly known as Scythian Biosciences Corp.) Mr. Scorsis also currently serves as the Chairman of Entourage Health Corp. (since February 2019) and Chairman of AWAKN Life Sciences (since January 2017), both of which are publicly traded on the TSX Venture Exchange and NEO Exchange.

George Scorsis, newly appointed Chairman of the Shuttle Pharma Board of Directors, commented, “I am honored to take on the role of Chairman of Shuttle Pharma. The Company has a unique opportunity to leverage its radiation sensitizers to increase cancer cure rates, prolong patient survival and improve quality of life for patients suffering from glioblastoma. I look forward to providing guidance to support the Company as we look to improve the lives of millions of patients impacted by cancer.”

About Shuttle Pharmaceuticals

Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.

Safe Harbor Statement

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning the development of our company. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the “Risk Factors” section of Shuttle Pharma’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, as well as the Company’s other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Shuttle Pharmaceuticals
Chris Cooper
Chief Executive Officer 
info@shuttlepharma.com

Investor Contacts
Lytham Partners, LLC
shph@lythampartners.com 

FAQ

Who is the new Chairman of Shuttle Pharmaceuticals (SHPH)?

George Scorsis has been appointed as the new Chairman of Shuttle Pharmaceuticals' Board of Directors, effective June 4, 2025.

What is George Scorsis's experience before joining Shuttle Pharmaceuticals (SHPH)?

George Scorsis has over 25 years of experience leading companies in regulated industries, including roles as President at Mettrum Health Corp, CEO of Liberty Health Sciences, and Chairman positions at SOL Global Investments, Entourage Health Corp, and AWAKN Life Sciences.

What is Shuttle Pharmaceuticals' (SHPH) main business focus?

Shuttle Pharmaceuticals is a specialty pharmaceutical company focused on developing radiation sensitizers to improve outcomes for cancer patients treated with radiation therapy.

How long has George Scorsis been associated with Shuttle Pharmaceuticals (SHPH)?

George Scorsis has served as a director of Shuttle Pharmaceuticals since February 2025 before being appointed Chairman in June 2025.

What is Shuttle Pharmaceuticals' (SHPH) mission in cancer treatment?

Shuttle Pharmaceuticals aims to improve cancer cure rates, prolong patient survival, and enhance quality of life by developing therapies that maximize the effectiveness of radiation therapy while limiting side effects.